Cagrilintide
Cagrilintide (AM833 / NNC0174-0833 / NN9838), a long-acting acylated amylin analogue [PMID 34288673; ClinicalTrials.gov orgStudyIdInfo NN9838-4942]
Clinical trials are ongoing or recently completed. Final approval has not been granted.
An investigational once-weekly injection that mimics amylin (a natural hormone your body uses to control appetite), being developed for weight loss and type 2 diabetes. Clinical trials show 10-12% body weight loss on its own, and up to 23% when combined with semaglutide.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
In Phase 2 (NCT03856047): nausea 20-47% cagrilintide versus 18% placebo; constipation 8-21% versus 7%; diarrhea 7-18% versus 9%; vomiting 5-9% versus 3%; injection-site reactions 4-12% versus 0% [NCT03856047; PMID 34798060]. In Phase 2 T2D trial: mostly mild-moderate GI events; no level 2 or 3 hypoglycemia reported [PMID 37364590]. REDEFINE 1: GI events 79.6% CagriSema versus 39.9% placebo, mainly transient and mild-moderate [PMID 40544433]. REDEFINE 2: GI events 72.5% CagriSema versus 34.4% placebo [PMID 40544432]. Discontinuation due to AEs 6-8.4% in Phase 3. Hypotension reported in 1.8% CagriSema versus 0.4% placebo in REDEFINE 1 BP analysis [PMID 41328546]. Meta-analysis of 4 RCTs confirmed GI AEs more frequent with CagriSema (RR 1.32) [PMID 41759565].
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-10]